Healthcare Professionals

At Orchard, we’re committed to working closely with physicians and others in the healthcare community to advance research into ex vivo autologous gene therapy and improve outcomes for people affected by rare inherited diseases.

Learn more about our gene therapy approach 

Learn more about our investigational therapies and clinical trials

MEDICAL INFORMATION

Healthcare providers requesting information on Orchard’s approved or pipeline programs may contact medinfo@orchard-tx.com.

PRODUCTS

Strimvelis

Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) is a gammaretroviral vector-based gene therapy approved by the European Medicines Agency (EMA) in 2016. It was the first ex vivo autologous gene therapy approved by the EMA. Strimvelis has not been approved by the U.S. Food and Drug Administration (FDA) or any other Health Authority.

Strimvelis is indicated for the treatment of patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), for whom no suitable human leukocyte antigen (HLA) matched related stem cell donor is available.  Strimvelis is intended solely for autologous use and must be given in a specialized hospital by a doctor who is experienced in treating patients with ADA-SCID and in using this type of medicine.

Serious adverse reactions include autoimmunity (e.g., autoimmune haemolytic anaemia, autoimmune aplastic anaemia, autoimmune hepatitis, autoimmune thrombocytopenia and Guillain-Barré syndrome). The most commonly reported adverse reaction was pyrexia.

For more information about Strimvelis, please see the EU Summary of Product Characteristics available on the EMA website.

ADVERSE EVENTS

To report an adverse event or side effect, contact us at OrchardPostPVG.SM@ppdi.com. For all other medical inquiries, healthcare providers may contact medinfo@orchard-tx.com.

RESOURCES

Read Orchard’s access policy

Independent Medical Education
Orchard supports independent medical education on our therapeutic areas of interest and on emerging developments in gene therapy. For more information and to apply, please contact medinfo@orchard-tx.com.

Investigator-initiated Research
Orchard supports investigator-initiated research on the diagnosis, natural history and other topics relevant to our indications. For more information and to apply, please contact medinfo@orchard-tx.com.

CLINICAL TRIALS

Orchard and our research partners are conducting clinical trials of investigational gene therapies for a number of rare, inherited diseases, including primary immune deficiencies, diseases of the brain and blood disorders. For more information about these trials, explore our pipeline or contact a member of Orchard medical information at medinfo@orchard-tx.com.

Title of the wysi

The site uses cookies to provide you with a more responsive and personalized service. By using this site, you agree to our use of cookies as set out in our cookie policy.

Please read our privacy policy and cookie policy for more information on the cookies we use and how to delete or block the use of cookies.